Startseite>>Infectious Disease>> Parasitic Diseases>> Trichomoniasis>>Metronidazole-d4

Metronidazole-d4

Katalog-Nr.GC47670

An internal standard for the quantification of metronidazole

Products are for research use only. Not for human use. We do not sell to patients.

Metronidazole-d4 Chemische Struktur

Cas No.: 1261392-47-5

Größe Preis Lagerbestand Menge
1 mg
506,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

Metronidazole-d4 is intended for use as an internal standard for the quantification of metronidazole by GC- or LC-MS. Metronidazole is an antibiotic that has activity against anaerobic bacteria and protozoa including T. vaginalis, E. histolytica, G. lamblia, C. difficile, and H. pylori.1 It reduces the growth of E. coli in vitro (MIC = 128 mg/L under anaerobic conditions).2 In vivo, metronidazole reduces viable counts of B. fragilis in a rabbit model of infection. Formulations containing metronidazole have been used in the treatment of various infections including H. pylori and C. difficile.

1.Samuelson, J.Why metronidazole is active against both bacteria and parasitesAntimicrob. Agents Chemother.43(7)1533-1541(1999) 2.Rylander, M., Holm, S.E., Brorson, J.-E., et al.Activity of metronidazole on Bacteroides fragilis and/or Escherichia coli in vitro and in vivoJ. Antimicrob. Chemother.7(3)257-267(1981)

Bewertungen

Review for Metronidazole-d4

Average Rating: 5 ★★★★★ (Based on Reviews and 22 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Metronidazole-d4

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.